Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting
No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients
Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…Abstract Number: 504 • 2017 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients
Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in active rheumatoid arthritis…Abstract Number: 505 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Stability of the RA Biomarkers RF and ACPA in Classifying RA Subtypes over Extended Follow up
Background/Purpose: In recent years several studies suggest that first order stratification of RA should be based on the presence or absence of rheumatoid factor (RF)…Abstract Number: 556 • 2016 ACR/ARHP Annual Meeting
Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity
Background/Purpose: Biomarkers in patients with rheumatoid arthritis (RA) have the attractive potential to help select patients that have a greater burden of disease activity and…Abstract Number: 651 • 2016 ACR/ARHP Annual Meeting
Calprotectin Serum Levels Strongly Predict Disease Flare in RA and Psa Patients with Low Disease Activity Treated with TNF Inhibitors. a One-Year Prospective Cohort Study
Background/Purpose: An increasing number of RA and PsA patients achieve low levels of disease activity under biological therapy. Thus, new biomarkers are needed to stratify…Abstract Number: 916 • 2016 ACR/ARHP Annual Meeting
Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Background/Purpose: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), have multifactorial pathogenesis associated with failure of immune tolerance. Advances in understanding the disease immunopathology have led…Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting
Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…Abstract Number: 1628 • 2016 ACR/ARHP Annual Meeting
Distinct Baseline Serum Molecular Profile and Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Asian-Pacific Patients with Active Rheumatoid Arthritis Despite DMARD or Anti-Tnfα Therapy Across Two Global Phase 3 Trials
Background/Purpose: Baseline differences in rheumatoid arthritis (RA) disease characteristics and molecular profile across populations may be a reflection of genetic variations and environmental factors such…Abstract Number: 1630 • 2016 ACR/ARHP Annual Meeting
Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis
Background/Purpose: The efficacy of sirukumab, an anti-IL-6 cytokine antibody, was evaluated in multiple phase 3 studies in patients with rheumatoid arthritis (RA) (SIRROUND -M, -D,…Abstract Number: 2615 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors
Background/Purpose: Patients with RA develop bone and joint damage due to chronic synovial inflammation that is mediated by specific cytokines.1 Cytokines (eg, IL-6) recruit activated…Abstract Number: 2616 • 2016 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients
Methods : Patients with active RA on stable dose of MTX were randomized 1:1:1:1:1:1:1 in a double blind manner to receive either placebo (PBO) or…Abstract Number: 2626 • 2016 ACR/ARHP Annual Meeting
Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints and infiltration by activated macrophages. TNFa is a central…Abstract Number: 2634 • 2016 ACR/ARHP Annual Meeting
Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Background/Purpose: Mavrilimumab is an anti-GM-CSF receptor Ab that has recently demonstrated clinical efficacy in Phase 2 studies in rheumatoid arthritis (RA) patients. Predictive biomarkers to…Abstract Number: 2648 • 2016 ACR/ARHP Annual Meeting
Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Background/Purpose: discovery of biomarkers that can identify pretreatment patients who will respond to biologic DMARDs therapy is one of the major interests in RA. We…Abstract Number: 3196 • 2015 ACR/ARHP Annual Meeting
Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Background/Purpose: In early rheumatoid arthritis (eRA), a clinically significant proportion of patients may respond to first-line treatment with methotrexate (MTX). A priori identification of patients…
ACR Meeting Abstracts